ArticleBone marrow transplantation2009
Selective apoptosis of monocytes and monocyte-derived DCs induced by bortezomib (Velcade).
Article in Bone marrow transplantation, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 24 citations in OpenAlex.
- The Proteasome Inhibitor Bortezomib Induces Apoptosis and Activation in Gel-Filtered Human Platelets.International journal of molecular sciences · 2021Article
- Inhibiting the immunoproteasome's β5i catalytic activity affects human peripheral blood-derived immune cell viability.Pharmacology research & perspectives · 2019Article
- Challenges in preventing and treating hemolytic complications associated with red blood cell transfusion.Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine · 2019Review
- On the role of the immunoproteasome in transplant rejection.Immunogenetics · 2019Review
- Impaired efferocytosis by monocytes in multiple myeloma.Oncology letters · 2018Article
- Type-2 cannabinoid receptor regulates proliferation, apoptosis, differentiation, and OPG/RANKL ratio of MC3T3-E1 cells exposed to Titanium particles.Molecular and cellular biochemistry · 2015Article
- The SOCS3-independent expression of IDO2 supports the homeostatic generation of T regulatory cells by human dendritic cells.Journal of immunology (Baltimore, Md. : 1950) · 2014Article
- Article
- Protection against titanium particle-induced inflammatory osteolysis by the proteasome inhibitor bortezomib in vivo.Inflammation · 2012Article
- The humanized anti-HLA-DR moAb, IMMU-114, depletes APCs and reduces alloreactive T cells: implications for preventing GVHD.Bone marrow transplantation · 2012Article
- Targeting multiple-myeloma-induced immune dysfunction to improve immunotherapy outcomes.Clinical & developmental immunology · 2012Review
- Proteasome inhibition and allogeneic hematopoietic stem cell transplantation: a review.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2009Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bortezomib, a proteasome inhibitor, has shown immunosuppressive activity in animal models of GVHD. In this study, we evaluated the effects of Bortezomib on the survival of monocytes, a major circulating source of DCs. PBMCs or purified CD14+ monocytes were cultured for 24 h with Bortezomib (0.1-100 ng/ml). Apoptosis was demonstrated on the basis of detection of phosphatydilserine. Bortezomib induced a significant dose-dependent depletion (P=0.008) of monocytes in PBMC preparations, with <1% CD14+ cells remaining at doses >or=5 ng/ml. Moreover, Bortezomib decreased the survival of purified monocytes within 24 h (P=0.004) (n=6). Monocyte loss was due to apoptosis (effective dose 50%, ED(50), 1-10 ng/ml). In addition, both immature and mature monocyte-derived DC underwent apoptosis following exposure to Bortezomib. Kinetic experiments showed that apoptosis increased at 16 h through 24 h of culture. However, short term (4 h) incubation with Bortezomib irreversibly committed monocytes to undergo apoptosis at 24, 72 and 144 h. Instead, Bortezomib induced no apoptosis of purified CD19+ B, CD3+ T lymphocytes and CD34+ progenitor cells (ED(50) >50 ng/ml). The inhibitory effect of Bortezomib on professional APCs, such as monocytes and DCs, suggests its possible use in GVHD prophylaxis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.